Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All budesonide studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 71% Improvement Relative Risk Budesonide  Ramlall et al.  INTUBATED PATIENTS Is very late treatment with budesonide beneficial for COVID-19? Retrospective 948 patients in the USA Lower mortality with budesonide (p=0.014) c19early.org Ramlall et al., medRxiv, October 2020 Favors budesonide Favors control

Melatonin is significantly associated with survival of intubated COVID-19 patients

Ramlall et al., medRxiv, doi:10.1101/2020.10.15.20213546
Oct 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 948 intubated patients, 33 treated with budesonide, showing lower mortality with treatment.
This study includes budesonide and melatonin.
risk of death, 71.0% lower, HR 0.29, p = 0.01, treatment 33, control 915, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ramlall et al., 18 Oct 2020, retrospective, USA, preprint, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBudesonideAll
Melatonin is significantly associated with survival of intubated COVID-19 patients
Vijendra Ramlall, Jason Zucker, Nicholas Tatonetti
doi:10.1101/2020.10.15.20213546
Background Respiratory distress requiring intubation is the most serious complication associated with coronavirus disease 2019 . Methods In this retrospective study, we used survival analysis to determine whether or not mortality following intubation was associated with hormone exposure in patients treated at New York Presbyterian/ Columbia University Irving Medical Center. Here, we report the overall hazards ratio for each hormone for exposure before and after intubation for intubated and mechanically ventilated patients. Results Among the 189,987 patients, we identified 948 intubation periods across 791 patients who were diagnosed with COVID-19 or infected with SARS-CoV2 and 3,497 intubation periods across 2,981 patients who were not. Melatonin exposure after intubation was statistically associated with a positive outcome in COVID-19 (demographics and comorbidities adjusted HR: 0.131, 95% CI: 7.76E-02 -0.223, p-value = 8.19E-14) and non-COVID-19 (demographics and comorbidities adjusted HR: 0.278, 95% CI: 0.142 -0.542, p-value = 1.72E-04) intubated patients. Additionally, melatonin exposure after intubation was statically associated with a positive outcome in COVID-19 patients (demographics and comorbidities adjusted HR: 0.127, 95% CI: 6.01E-02 -0.269, p-value = 7.15E-08). Conclusions Melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 and non-COVID-19 patients. Additionally, melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 patients requiring mechanical ventilation. While our models account for many covariates, including clinical history and demographics, it is impossible to rule out confounding or collider biases within our population. Further study into the possible mechanism of this observation is warranted.
Competing interests The authors declare no competing interests.
References
Beigel, Remdesivir for the treatment of Covid-19-Preliminary Report, N. Engl. J. Med
Boulware, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N. Engl. J. Med
Chakravarty, Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer, Commun. Biol
Fan, COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?, Lancet
Funk, Snapshot of the Global Race for Vaccines Targeting SARS-CoV2 and the COVID-19 Pandemic, Front Pharmacol, doi:10.3389/fphar.2020.00937
Geleris, Observation Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med
Grady, Covid-19 Patient Gets Double Lung Transplant, Offering Hope for Others
Jean, Treatment options for COVID-19: The reality and challenges, J. Microbiol. Immunol. Infect
Lamamri, Priapism in a patient with coronavirus disease 2019 (COVID-19): A case report, Am. J. Emerg. Med
Li, Estimated Demand for US Hospital Impatient and Intensive Care Unit Beds for Patients with COVID-19 Based on Comparisons with Wuhan and Guangzhou, China, JAMA Netw, doi:Open.10.1001/jamanetworkopen.2020.8297
Moderna, Moderna's Work on a COVID-9 Vaccine Candidate
Ramlall, Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV2 infection, Nat. Med
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit